Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 20/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14639038 | 0.72 | MKNK1 (0.49) | — | |
| SCHEMBL7711671 | 0.69 | EGLN2 (0.53) | EGLN2 | |
| SCHEMBL19510416 | 0.69 | EGLN2 (0.58) | EGLN2 | |
| SCHEMBL21816409 | 0.69 | EGLN2 (0.53) | EGLN2 | |
| SCHEMBL22235060 | 0.68 | EGLN2 (0.47) | EGLN2 | |
| SCHEMBL59543 | 0.67 | MAP4K4 (0.41) | — | |
| SCHEMBL20276953 | 0.67 | ALDH1A1 (0.30) | — | |
| SCHEMBL13390665 | 0.67 | NUDT1 (0.51) | EGLN2 | |
| SCHEMBL19732286 | 0.67 | EGLN2 (0.35) | EGLN2 | |
| SCHEMBL3302899 | 0.67 | AHR (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138987-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12565501-B2 | Muscarinic acetylcholine M1 receptor antagonists | CONTINEUM THERAPEUTICS, INC. (US) | 2026-03-03 | — | — | US | disclosed |
| US-20250171455-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS INC (US) | 2025-05-29 | — | — | US | disclosed |
| US-20250026758-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS INC (US) | 2025-01-23 | — | — | US | disclosed |
| CN-119112895-A | Muscarinic acetylcholine M1 receptor antagonists | 康蒂内乌姆医疗公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-112638381-B | Muscarinic acetylcholine M1 receptor antagonists | 康蒂内乌姆医疗公司 | 2024-08-30 | — | — | CN | disclosed |
| US-12054487-B2 | Muscarinic acetylcholine M1 receptor antagonists | CONTINEUM THERAPEUTICS, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| US-20230089921-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS, INC. | 2023-03-23 | — | — | US | disclosed |
| US-11512090-B2 | Muscarinic acetylcholine M1 receptor antagonists | Pipeline Therapeutics, Inc. (US) | 2022-11-29 | — | — | US | disclosed |
| US-20220332721-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS, INC. | 2022-10-20 | — | — | US | disclosed |
| CN-114729044-A | Muscarinic acetylcholine M1Receptor antagonists | 帕珀莱恩医疗公司 | 2022-07-08 | — | — | CN | disclosed |
| EP-3846806-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | Pipeline Therapeutics, Inc. (US) | 2021-07-14 | — | — | EP | disclosed |
| US-20210155629-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS, INC. | 2021-05-27 | — | — | US | disclosed |
| US-20210155629-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS, INC. | 2021-05-27 | — | — | US | disclosed |
| WO-2021071843-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | Pipeline Therapeutics, Inc. (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021071843-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | Pipeline Therapeutics, Inc. (US) | 2021-04-15 | — | — | WO | disclosed |
| CN-112638381-A | Muscarinic acetylcholine M1 receptor antagonists | 帕珀莱恩医疗公司 | 2021-04-09 | — | — | CN | disclosed |
| EP-3728249-A1 | 1H -PYRAZOLO[4,3-b ]PYRIDINES AS PDE1 INHIBITORS | H. Lundbeck A/S (DK) | 2020-10-28 | — | — | EP | disclosed |
| US-10766893-B2 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2020-09-08 | — | — | US | disclosed |
| US-20190194189-A1 | 1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210155629-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CHRM1, CHRM2, CHRM5 | EGLN2 4883/4885 |
| US-10766893-B2 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | PDE12, PDE3B, PDE5A | EGLN2 2488/4885 |
| US-12054487-B2 | Muscarinic acetylcholine M1 receptor antagonists | CHRM1, CHRM2, CHRM3 | EGLN2 4883/4885 |
| US-12565501-B2 | Muscarinic acetylcholine M1 receptor antagonists | CHRM1, CHRM2, CHRM3 | EGLN2 4884/4885 |
| US-20220332721-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CHRM1, CHRM2, CHRM5 | EGLN2 4883/4885 |
| US-20230089921-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CHRM1, CHRM2, CHRM3 | EGLN2 4884/4885 |
| US-20190194189-A1 | 1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS | PDE12, PDE3B, PDE5A | EGLN2 2488/4885 |
| US-20260138987-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CHRM1, CHRM5, CHRM3 | EGLN2 4884/4885 |
| US-20250026758-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CHRM1, CHRM2, CHRM5 | EGLN2 4883/4885 |
| US-20250171455-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CHRM1, CHRM2, CHRM3 | EGLN2 4884/4885 |
| US-11512090-B2 | Muscarinic acetylcholine M1 receptor antagonists | CHRM1, CHRM2, CHRM5 | EGLN2 4883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.